Keith Edwards, M.D.


Keith Edwards, M.D. is the Director of the MS Center of Northeastern New York in Latham, NY and is affiliated with Ellis Hospital, Schenectady, NY. He has been board certified in neurology since 1978. After earning his medical degree from Duke Medical School, Durham, NC, Dr. Edwards completed a medical internship at Boston City Hospital and a neurology residency at the University of Vermont School of Medicine, Burlington, Vermont. Dr. Edwards trained under Dr. George Schumacher and Dr. Charles Poser concentrating in clinical care and research in multiple sclerosis. Dr. Edwards has been involved with multiple sclerosis and Alzheimers evaluation, treatment and research for 30 years. He has been involved in NIH supported research in neurotransmitters, National MS Society grants in genetic research, individual research grants and multicenter treatment trials. Dr. Edwards has served on many scientific advisory committees and editorial boards. His work has been published in numerous scientific journals including Neurology,Clinical Journal of Pharmacology, Multiple Sclerosis, Archives of Neurology, and Biochemical Pharmacologyand others. He is also the author of book chapters and many Internet articles. He has lectured nationally and internationally. He has been involved with Dementia, neuropathic pain and headache evaluation, treatment and research for over 30 years. He participated in many multi-centered treatment trials for new pain and headache medications as well as many new Alzheimer's medications.

In this section, we provide you information about important publications and abstracts by Dr. Edwards in many scientific journals in the last five years. This section is regularly updated. For a complete list of Dr. Edwards publication listings, please click the link below.

Complete List of Publications by Dr. Edwards Courtesy of Google Scholar

Full papers of Dr. Edwards' publications in refereed journals between 2009-2016:
    1. ♦ Multiple Sclerosis Journal 2015
    2. Goodman AD, Bethoux F, Brown TR, Edwards K et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extension of two Phase 3 clinical trials  Mult Scler 2015; 21: 1322-1331
    3. ♦ BMC Neurology 2014
    4. Calkwood J, Cree B, Crayton H, Kantor D, Edwards K, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient-and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial  BMC Neurology  2014; 14: 220
    5. ♦ Multiple Sclerosis & Related Disorders 2014
    6. Fox E, Edwards K, Burch G, Wynn DR et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis Multiple Sclerosis and related Disorders 2014; 3: 607-619
    7. ♦ Plos One 2013
    8. Keith R. Edwards, Jaya Goyal, et al.Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis   Plos One  Nov 2013;
    9. ♦ Journal Of MS Care 2012
    10. Edwards K, Goodman W, Ma C. Improvement of neuropsychological function in cognitively impaired multiple sclerosis patients treated with natalizumab. Int. Journal of MS Care 2012; 14:100-104
    11. ♦ Multiple Sclerosis Journal 2012
    12. Nielsen S, Miravalle A, Langer-Gould A, Cooper J, Edwards K, Kinkel P. B cell depletion and safety of low dose rituximab in patients with relapsing multiple sclerosis. Mult Scler 2012; 18:377-378
    13. ♦ Annals Of Neurology 2010
    14. Goodman A, Brown T, Edwards K, Krupp L, Schapiro R, Cohen R, et al Confirmatory Phase 3 Trial of Sustained Release Oral Fampridine in Multiple Sclerosis. Annals of Neurology 2010; 68:494-502
    15. ♦ Cancer 2009
    16. Glantz M, Chamberlain M, Liu Q, Hsieh C, Edwards K, Horn A, Recht L. Gender disparity in the rate of partner abandonment in patients with serious medical illness. Cancer 2009 115:5237-5242.
    17. ♦ Neurology 2009
    18. Cohen J, Imrey P, Calabresi P, Edwards K, Eikenhorst T, Felton III W, Fisher E, Fox R, Goodman A, Hara-Cleaver C, Hutton G, Mandell B, Scott T, Zang H, Apperson-Hansen C et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009 72:535-541.
Dr. Edwards is a Fellow of the American Academy of Neurology, a member of the National Multiple Sclerosis Society, the Consortium of Multiple Sclerosis Centers (CMSC) and the NY State Consortium of MS Centers. He is also a Fellow of the American Headache Society, International Headache Consortium and the Alzheimer's Society.   He is on the Professional Advisory Board of the National Multiple Society and the Advisory Board of the New York State Consortium of MS Centers. He is also the Vice President of the Italia-America Cultural Foundation of New York, Inc.